Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study.

نویسندگان

  • Alfred K Cheung
  • Nathan W Levin
  • Tom Greene
  • Lawrence Agodoa
  • James Bailey
  • Gerald Beck
  • William Clark
  • Andrew S Levey
  • John K Leypoldt
  • Daniel B Ornt
  • Michael V Rocco
  • Gerald Schulman
  • Steve Schwab
  • Brendan Teehan
  • Garabed Eknoyan
چکیده

Among the 1846 patients in the HEMO Study, chronic high-flux dialysis did not significantly affect the primary outcome of the all-cause mortality (ACM) rate or the main secondary composite outcomes, including the rates of first cardiac hospitalization or ACM, first infectious hospitalization or ACM, first 15% decrease in serum albumin levels or ACM, or all non-vascular access-related hospitalizations. The high-flux intervention, however, seemed to be associated with reduced risks of specific cardiac-related events. The relative risks (RR) for the high-flux arm, compared with the low-flux arm, were 0.80 [95% confidence interval (CI), 0.65 to 0.99] for cardiac death and 0.87 (95% CI, 0.76 to 1.00) for the composite of first cardiac hospitalization or cardiac death. Also, the effect of high-flux dialysis on ACM seemed to vary, depending on the duration of prior dialysis. This report presents secondary analyses to further explore the relationship between the flux intervention and the duration of dialysis with respect to various outcomes. The patients were stratified into a short-duration group and a long-duration group, on the basis of the mean duration of dialysis of 3.7 yr before randomization. In the subgroup that had been on dialysis for >3.7 yr, randomization to high-flux dialysis was associated with lower risks of ACM (RR, 0.68; 95% CI, 0.53 to 0.86; P = 0.001), the composite of first albumin level decrease or ACM (RR, 0.74; 95% CI, 0.60 to 0.91; P = 0.005), and cardiac deaths (RR, 0.63; 95% CI, 0.43 to 0.92; P = 0.016), compared with low-flux dialysis. No significant differences were observed in outcomes related to infection for either duration subgroup, however, and the trends for beneficial effects of high-flux dialysis on ACM rates were considerably weakened when the years of dialysis during the follow-up phase were combined with the prestudy years of dialysis in the analysis. For the subgroup of patients with <3.7 yr of dialysis before the study, assignment to high-flux dialysis had no significant effect on any of the examined clinical outcomes. These data suggest that high-flux dialysis might have a beneficial effect on cardiac outcomes. Because these results are derived from multiple statistical comparisons, however, they must be interpreted with caution. The subgroup results that demonstrate that patients with different durations of dialysis are affected differently by high-flux dialysis are interesting and require further study for confirmation.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Dialyzer Reuse and Outcomes of High Flux Dialysis

BACKGROUND The bulk of randomized trial evidence for the expanding use of High Flux (HF) hemodialysis worldwide comes from two randomized controlled trials, one of which (HEMODIALYSIS, HEMO) allowed, while the other (Membrane Outcomes Permeability, MPO) excluded, the reuse of membranes. It is not known whether dialyzer reuse has a differential impact on outcomes with HF vs low flyx (LF) dialyze...

متن کامل

High-frequency hemodialysis: rationale for randomized clinical trials.

H undreds of thousands of people with end-stage renal failure are alive today because they receive treatment with hemodialysis. Although kidney transplantation and peritoneal dialysis also are available to treat kidney failure, in-center hemodialysis remains the predominant form of renal replacement therapy in North America. Despite its dramatic success at saving lives, hemodialysis is far from...

متن کامل

The HEMO Study: applicability and generalizability.

The 2002 Lasker Clinical Medical Research Award honoured Willem Kolff and Belding Scribner, whose seminal work changed kidney failure from a fatal to a treatable disease. What began as exploratory efforts to sustain life and relieve uraemic symptoms in selected patients now provides chronic life-saving replacement therapy to millions of people worldwide. Continued improvements in clinical exper...

متن کامل

The Booster Phenomenon of Tuberculin Skin Testing in Patients Receiving Hemo-dialysis

Background: The risk of developing tuberculosis is high among chronic hemodialysis patients. The tuberculin skin test (TST) has been in use for diagnosing latent TB, but few data are available on TST in hemodialysis patients. Objective: This study was done to identify the TST reactivity and frequency of booster effect in serial TST among hemodialysis patients. Methods: A total of 100 patients i...

متن کامل

Design and statistical issues of the hemodialysis (HEMO) study.

The Hemodialysis Study is a multicenter clinical trial of hemodialysis prescriptions for patients with end stage renal disease. Participants from over 65 dialysis facilities associated with 15 clinical centers in the United States are randomized in a 2 x 2 factorial design to dialysis prescriptions targeted to a standard dose or a high dose, and to either low or high flux membranes. The primary...

متن کامل

How will the results of the HEMO study impact dialysis practice?

Uremia is the clinical consequence of poor renal function and is also the target of hemodialysis (HD) therapy. In the absence of a comprehensive understanding of uremia, the optimum therapy for an average patient with end-stage renal disease (ESRD) can be discovered by observing outcomes during a large clinical trial with randomly assigned dialysis options. The HEMO study was an ambitious effor...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of the American Society of Nephrology : JASN

دوره 14 12  شماره 

صفحات  -

تاریخ انتشار 2003